Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 9/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MAP2 | P11137 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | CCNC | P24863 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.38 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL980179 | 0.91 | IDO1 (0.46) | IDO1CYP3A4HPGDSCYP2E1CYP2D6 | |
| SCHEMBL2848953 | 0.81 | ADORA2A (0.46) | MAP2FYNADORA2A | |
| SCHEMBL986290 | 0.79 | DYRK1B (0.39) | CYP3A4MAP2CDC7CCNCCDK8 | |
| Formamide SCHEMBL29058737 | 0.76 | ADORA2A (0.42) | MAP2FYNADORA2A | |
| SCHEMBL986288 | 0.74 | FYN (0.38) | CYP3A4CDC7CDK8FYNCSF1R | |
| SCHEMBL23067310 | 0.72 | MAP2K3 (0.50) | CYP3A4CYP2C9MAP2CDC7ADORA2A | |
| SCHEMBL19900630 | 0.71 | MAP2K1 (0.38) | CYP3A4CYP2D6CYP2C9CYP2C19MAP2 | |
| SCHEMBL980970 | 0.71 | FYN (0.40) | CYP3A4CDC7FYNCSF1RADORA2A | |
| Benzamide SCHEMBL27802955 | 0.70 | CYP3A4 (0.47) | IDO1CYP3A4HPGDSCYP2C19FYN | |
| SCHEMBL4340971 | 0.69 | CDC7 (0.36) | MAP2CDC7CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170196844-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2017-07-13 | — | — | US | disclosed |
| US-9586932-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160130251-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2016-05-12 | — | — | US | disclosed |
| US-9067933-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20140018370-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2014-01-16 | — | — | US | disclosed |
| US-8598360-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-8552196-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8378108-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20130035339-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130012521-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018370-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, CASP6 | IDO1 3087/4885CYP3A4 3926/4885HPGDS 1457/4885 |
| US-20170196844-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, CASP6 | IDO1 3087/4885CYP3A4 3926/4885HPGDS 1457/4885 |
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, AIFM1 | IDO1 2957/4885CYP3A4 3824/4885HPGDS 1340/4885 |
| US-20160130251-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, CASP6 | IDO1 3087/4885CYP3A4 3926/4885HPGDS 1457/4885 |
| US-20130035339-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, MAP3K6 | IDO1 2881/4885CYP3A4 3618/4885HPGDS 1446/4885 |
| US-20130012521-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, CASP6 | IDO1 3087/4885CYP3A4 3926/4885HPGDS 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.